Prerakkumar Parikh, PharmD, of Megallen Rx Management/Prime Therapeutics, detailed the impact of formulary placement of biosimilars on cost burden along with how stakeholders can work with pharmacy benefit managers to promote biosimilar use.
Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, explains the roles of formulary placement and tiering by pharmacy benefit managers (PBMs) in relation to biosimilars and how they affect the cost-sharing burden for patients who choose them. He also discusses how stakeholders, like health care providers and policymakers, can work with PBMs to promote the use of biosimilars.
Parikh went into more detail on biosimilars during the AMCP Nexus session, "Biosimilar Operational Readiness: Managed Care Stakeholder Response to Market Expansion Impact.
Transcript
Can you explain the roles of formulary placement and tiering by PBMs? How do these decisions affect the cost-sharing burden for patients who choose biosimilars over reference biologics?
The tiering, some of the biosimilars that have came out are in the specialty tier. So far on the pharmacy benefit side, we are seeing the adalimumab biosimilars on that specialty tier along with the brand name product, Humira.
So, what that will do is it will allow for access. At the same time, if you have a low-WAC [wholesale acquisition cost] biosimilar at the same level as Humira, and if a patient is paying a percentage coinsurance on that specialty tier, a low-WAC biosimilar is going to reduce that cost for the patient, as well.
How can stakeholders, including policymakers, manufacturers, and health care providers, work with PBMs to promote biosimilars and encourage adoption?
The biggest factor into promoting biosimilar use and encouraging the use will be to educate patients and educate providers. I think we as an industry, all the stakeholders, need to make sure that we have resources that help the providers and the patients understand the value of biosimilars, the cost savings from biosimilars, and, at the same time, how biosimilars have the same clinical efficacy and safety as the reference product.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More